Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
BRENTWOOD, TENNESSEE, UNITED STATES, January 25, 2024 /EINPresswire.com/ -- Currax Pharmaceuticals LLC (“Currax”) announces the first patient screened and accepted into the CONTRAVE® INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3). The initiation of …